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Lindsay E NicolleAbstract
Urinary tract infection attributed to the use of an indwelling urinary catheter is one of the most common infections
acquired by patients in health care facilities. As biofilm ultimately develops on all of these devices, the major
determinant for development of bacteriuria is duration of catheterization. While the proportion of bacteriuric
subjects who develop symptomatic infection is low, the high frequency of use of indwelling urinary catheters
means there is a substantial burden attributable to these infections. Catheter-acquired urinary infection is the source
for about 20% of episodes of health-care acquired bacteremia in acute care facilities, and over 50% in long term
care facilities. The most important interventions to prevent bacteriuria and infection are to limit indwelling catheter
use and, when catheter use is necessary, to discontinue the catheter as soon as clinically feasible. Infection control
programs in health care facilities must implement and monitor strategies to limit catheter-acquired urinary infection,
including surveillance of catheter use, appropriateness of catheter indications, and complications. Ultimately, prevention
of these infections will require technical advances in catheter materials which prevent biofilm formation.
Keywords: Urinary catheter, Bacteriuria, Urinary tract infection, Health care acquired infection, Indwelling
urethral catheterReview
Introduction
Catheter acquired urinary tract infection is one of the
most common health care acquired infections [1,2]; 70–
80% of these infections are attributable to use of an
indwelling urethral catheter. Recent prevalence surveys
report a urinary catheter is the most common indwelling
device, with 17.5% of patients in 66 European hospitals
having a catheter [1] and 23.6% in 183 US hospitals [2].
In the NHSN 2011 surveillance report, 45–79% of pa-
tients in adult critical care units had an indwelling cath-
eter, 17% of those on medical wards, 23% on surgical
wards, and 9% on rehabilitation units [3]. Thus, indwelling
urethral catheter use is exceedingly common in health
care facilities. Prevention of infections attributable to these
devices is an important goal of health-care infection
prevention programs.
Indwelling urinary catheters are generally considered
to be short term if they are in situ for less than 30 days
and chronic or long term when in situ for 30 days or
more [4]. Indwelling catheter use in acute care facilitiesCorrespondence: lnicolle@exchange.hsc.mb.ca
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unless otherwise stated.is usually short term, while chronic catheters are most
common for residents of long term care facilities. Clin-
ical and microbiologic considerations may vary for short
and long term catheters. Urinary catheter acquired infec-
tion is usually manifested as asymptomatic bacteriuria
(CA-ASB). The term catheter associated urinary tract in-
fection (CA-UTI) is used to refer to individuals with
symptomatic infection [4]. In early reports, however,
asymptomatic and symptomatic catheter-acquired infec-
tion were often not differentiated. This review addresses
only indwelling urethral catheters, and will not discuss
use of intermittent catheters for men or women, or ex-
ternal catheters for men.Burden of illness
Asymptomatic bacteriuria
Duration of catheterization is the most important deter-
minant of bacteriuria [4]. The daily risk of acquisition of
bacteriuria when an indwelling catheter in situ is 3–7%.
The rate of acquisition is higher for women and older
persons [4]. Bacteriuria is universal once a catheter remains
in place for several weeks. Patients with chronic indwelling
catheters are assumed to be continuously bacteriuric.
From 60–80% of hospitalized patients with an indwelling
catheter receive antimicrobials, usually for indicationshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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microbial exposure means antimicrobial resistant organ-
isms are frequently isolated from the urine of catheterized
individuals. Statewide surveillance of carbapenemase re-
sistant Enterobacteriaceae (CRE) in Michigan reported
61% of isolates were from urine cultures, and a urinary
catheter was present in 48% of these patients [6]. Bacteria
colonizing the drainage bags of catheterized patients have
been reported to be a source for outbreaks of resistant or-
ganisms in acute care facilities [4,7]. In the nursing home
setting, the urine of residents with chronic indwelling
catheters is the most common site of isolation of resistant
gram negative organisms [8,9].
Symptomatic urinary tract infection
CA-UTI is the most common adverse event associated
with indwelling urinary catheter use (Table 1), although
only a small proportion of acute care facility residents
with CA-ASB develop symptomatic infection [10]. In the
European prevalence survey, 1.3% of patients had urin-
ary infection, representing 17.2% of all healthcare ac-
quired infections, and the third most frequent infection
[1]. The presence of any health care acquired infection
was independently associated with the number of inva-
sive devices, including indwelling urethral catheters, but
the proportion of patients with urinary infections and a
catheter was not reported. The recent US point preva-
lence survey reported urinary tract infection was the
fourth most common infection, accounting for 12.9% of
health care infections; 67.7% of these patients had a urinary
catheter [2]. At one Veteran’s Affairs (VA) hospital, 0.3% of
all urinary catheter days involved symptomatic UTI [11]. ATable 1 Recent reports describing incidence of
symptomatic catheter-acquired urinary infection
Country (ref) Population CA-UTI rate/1,000
catheter days
France [13] ICU 14.8 (1995);
8.8 (2004)
Germany [14] ICU 1.39 (before 2000),
0.83 (2001, 2002),
0.68 (2003 or later)
15 developing countries [15] ICU 7.86 (pre-intervention);
4.95 (post-intervention)






Cyprus [16] ICU 2.0 – 3.0comparative British trial evaluating different types of cathe-
ters reported rates of CA-UTI of 10.6%-12.6% of catheter-
ized patients, although only 3.2%-5.0% of infections were
microbiologically confirmed [12].
CA-UTI rates reported in ICU’s in the NHSN hospitals
declined by 18.5%-67% among different adult ICU’s be-
tween 1990 – 2007 [17] (Table 1). In France, a 66% reduc-
tion was reported over a 10-year surveillance period [13].
Some of this decrease is attributable to more intense pre-
vention efforts, but modification of definitions to exclude
asymptomatic bacteriuria has also contributed.
In US long term care facilities, 3–10% of residents are
managed with chronic indwelling catheters [18]. European
surveillance reports describe indwelling catheters being
present in 12% of residents in 10 nursing homes in the
Netherlands [19], 12.3% in 92 homes in Italy [20], and
10.1% in 40 homes in Germany [21]. The prevalence of
chronic indwelling catheters was 7% overall among resi-
dents of 78 nursing homes in Sweden, but was 16% for
men and only 3% for women [22]. Residents with chronic
catheters have an increased risk of symptomatic urinary
tract infection. CA-UTI rates of 0–7.3/1,000 catheter days
(mean 3.2/1,000) were reported in Idaho long term care
facilities [23]. The incidence of fever from a presumed
urinary source is 0.7–1.1/100 catheter days, which is three
times greater than observed for residents with bacteriuria
but without a urinary catheter [24,25].
Bacteremia
Less than 3% of subjects with CA-ASB develop bacteremia
with the urinary isolate [10] but, given the high frequency
of indwelling urinary catheter use, CA-UTI is one of the
most common causes of secondary bloodstream infection
in acute care facilities. During a 3 year period in Quebec,
21% of health care acquired bloodstream infections were
from a urinary source, and 71% of these were device associ-
ated. The incidence was 1.4 urinary bloodstream infections/
10,000 patient days. All cause 30 day mortality in patients
with CA-UTI bacteremia was 15% [26].
CA-UTI is the source of over 50% of episodes of
bacteremia in long term care facilities [4,27]. The risk of
bacteremia in residents with indwelling catheters in these
facilities is 3–36 times that of residents without an in-
dwelling catheter [28].
Other morbidity
Additional infectious complications, usually identified in
patients with a chronic indwelling catheter, include urin-
ary catheter obstruction, bladder urolithiasis, purulent ur-
ethritis, gland abscesses and, for males, prostatitis [24].
Non-infectious complications attributed to an indwelling
urinary catheter include nonbacterial urethral inflamma-
tion, urethral strictures, mechanical trauma, and mobility
impairment [29,30]. Prospective daily catheter surveillance
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the indwelling catheter on 1.5% of catheter days [11].
Several studies report an association of CA-UTI with in-
creased mortality and prolonged length of stay in acute
care facilities. For critical care unit patients, these associa-
tions are likely attributable to confounding by unmeasured
variables with little, if any, mortality directly attributable
to CA-UTI [31]. Long term care facility residents with
chronic indwelling catheters have an increased mortality
relative to residents without a catheter, but this observa-
tion is also attributable to confounding from variable pa-




Biofilm formation along the catheter surface is the most im-
portant cause of bacteriuria [33]. Biofilm is a complex or-
ganic material consisting of micro-organisms growing in
colonies within an extra-cellular mucopolysaccharide sub-
stance which they produce. Urine components, including
Tamm-Horsfall protein and magnesium and calcium ions,
are incorporated into this material. Biofilm formation begins
immediately after catheter insertion, when organisms adhere
to a conditioning film of host proteins which forms along
the catheter surface. Both the interior and exterior catheter
surfaces are involved. Bacteria usually originate from the
periurethral area or ascend the drainage tubing following
colonization of the drainage bag. Only about 5% of epi-
sodes of CA-ASB follow introduction of periurethral or-
ganisms into the bladder at the time of catheter insertion.
Organisms growing in the biofilm are in an environment
where they are relatively protected from antimicrobials and
host defenses. A single species is usually identified with the
initial episode of bacteriuria following insertion of an in-
dwelling catheter. If the catheter remains in situ and a ma-
ture biofilm develops, polymicrobial bacteriuria becomes
the norm. For individuals with long term indwelling cathe-
ters, 3–5 organisms are usually isolated [34,35]. The micro-
biology of biofilm on an indwelling catheter is dynamic
with continuing turnover of organisms in the biofilm while
the catheter remains in situ [36]. Patients continue to ac-
quire new organisms at a rate of about 3–7%/day.
The determinants of CA-UTI are not well described.
However, catheter trauma or catheter obstruction are well
recognized precipitating events. Risk factors for bloodstream
infection from a urinary source in acute care patients are
reported to be neutropenia, renal disease and male sex [37].
Bacteremia is not a significant complication of chronic in-
dwelling catheter replacement [28].
Microbiology
The most common infecting organism is Escherichia coli
[4]. Other Enterobacteriaceae as well as Enterococci spp,coagulase negative Staphylococcus, Pseudomonas aeruginosa,
other non-fermenters, and Candida spp are also fre-
quently isolated [24]. Antimicrobial-resistant organisms
are common. The urine of patients with indwelling cathe-
ters is the major site of isolation of resistant gram negative
organisms in both acute and long term care facilities, in-
cluding extended spectrum beta-lactamase (ESBL) produ-
cing Enterobacteriaceae [8] and CRE [6]. E. coli is usually
the most frequent species isolated from bacteremic CA-
UTI patients in acute care facilities (Table 2). However,
Enterococcus spp (28.4%) and Candida spp (19.7%) were
reported to be most common at one US tertiary care aca-
demic centre [38].
Proteus mirabilis is an organism of unique importance
for patients with chronic indwelling catheters. This species
is seldom isolated following initial colonization of the
catheterized urinary tract, so it is not common in patients
undergoing short term catheterization [42]. The longer a
catheter is in place the more likely P. mirabilis will be
present. This organism is isolated from about 40% of urine
samples collected from patients with chronic indwelling
catheters [43]. P. mirabilis produces more copious biofilm
than other bacteria, and these strains also tend to persist
for longer periods of time [36].
Bacterial species which produce urease may facilitate the
formation of a crystalline biofilm [44,45]. This material is
similar to struvite (infection) stones in patients with urolith-
iasis. Crusts of this material form along the catheter and
are the major cause of obstruction of chronic indwelling
catheters. About half of patients with chronic indwelling
catheters experience catheter blockage at some time, while
some patients experience rapid, recurrent obstruction
[46,47]. The urease of P. mirabilis hydrolyzes urea several
times faster than the urease produced by other organisms
[48]. This species is isolated from 80% of obstructed cathe-
ters [49]. Other urease producing species include P. aerugi-
nosa, Klebsiella pneumoniae, Morganella morganii, other
Proteus species, some Providencia spp and some strains of
Staphylococcus aureus and coagulase negative staphylo-
cocci. Urease production by many of these species, includ-
ing M. morganii, K. pneumoniae, and P. aeruginosa, does
not generate an alkaline urine, so these strains are seldom
associated with appreciable encrustation on catheters [50].
Diagnosis of CA-UTI
Microbiologic diagnosis
Urine specimens for culture should be collected directly
from the catheter or tubing, to maintain a closed drain-
age system. These may be collected either through the
catheter collection port or through puncture of the tub-
ing with a needle [4]. CA-ASB is diagnosed when one or
more organisms are present at quantitative counts ≥105
cful/ml from an appropriately collected urine specimen
in a patient with no symptoms attributable to urinary
Table 2 Species isolated from bacteremia attributed to catheter-acquired urinary infection
% of isolates
Population (ref) US* [38] UK [39] Quebec [26] US [40]** Europe [40]** Spain [41]
E. coli 43.4% 47% 69.3% 71.3% 42%
Klebsiella spp 7.5% 16.7% 11.2% 15%
Enterococcus spp 28.4% 6% 8% 12%
P. mirabilis 13.3% 6.4% 5.0% 7%
P. aeruginosa 10.8% 4.1% 12%
Candida spp 19.7% 2% 3%
*Tertiary care academic centre.
**Report for gram negative isolates only.
Nicolle Antimicrobial Resistance and Infection Control 2014, 3:23 Page 4 of 8
http://www.aricjournal.com/content/3/1/23infection [4]. Lower quantitative counts may be isolated
from urine specimens prior to ≥105 cfu/ml being present,
but these lower counts likely reflect the presence of or-
ganisms in biofilm forming along the catheter, rather
than bladder bacteriuria [5]. A mature biofilm has usually
formed once the catheter has been in situ for longer than
2 weeks. Urine collected through these catheters are con-
taminated by organisms present in the biofilm. There is a
greater number of species and quantity of organisms iso-
lated than these specimens compared with bladder urine
collected simultaneously. Thus, it is recommended that
the catheter be removed and a new catheter inserted, with
specimen collection from the freshly placed catheter,
before antimicrobial therapy is initiated for symptom-
atic infection [4]. Organisms isolated with quantitative
counts <105 cfu/ml from the replacement catheter tend
not to persist [51].
Clinical diagnosis
The diagnosis of symptomatic CA-UTI is often a diagno-
sis of exclusion [4,24]. Fever without localizing findings is
the usual presentation of CA-UTI. Localizing signs or
symptoms such as catheter obstruction, acute hematuria,
recent trauma, suprapubic pain, or costovertebral angle
pain or tenderness are helpful to identify a urinary source
of fever, but are present in only a minority of episodes of
presumed symptomatic infection. If localizing genitouri-
nary findings are not present, fever in bacteriuric patients
should be attributed to urinary infection only when there
are no other potential sources. When the same organism
is isolated from both the urine and a simultaneous blood
culture, a diagnosis of CA-UTI is presumed in the absence
of an alternate source for the bacteremia.
Pyuria
Bacteriuric patients usually have pyuria, irrespective of
symptoms. Patients with an indwelling catheter may also
have pyuria without bacteriuria, as the catheter itself may
cause bladder inflammation [10]. Other potential non-
infectious causes of pyuria include renal disease, such as
interstitial nephritis. Thus, the presence of pyuria in urinespecimens obtained from a patient with an indwelling
urinary catheter does not identify symptomatic infec-
tion in a bacteriuric subject, nor is it an indication for
antimicrobial therapy [4,28].
Prevention of catheter acquired urinary tract infections
Guidelines
Several evidence-based guidelines provide recommenda-
tions for the development and maintenance of preven-
tion programs for CA-UTI [4,7,52-54]. Approaches to
prevention include avoidance of catheter use, policies for
catheter insertion and maintenance, catheter selection,
surveillance of CA-UTI and catheter use, and recom-
mendations for quality indicators.
Program implementation
The facility infection prevention and control program
should incorporate measures to limit CA-UTI. Improved
outcomes following implementation of these programs
have been reported [15,55-57]. The program for a given
institution should be individualized to be relevant to local
experience, population characteristics, and resources. An
essential element of any program is leadership at the se-
nior management level [58].
Infrastructure to support an effective program includes
development of policies for catheter indications, catheter
selection, and catheter insertion and maintenance [4,7,52].
There must be sufficient staffing and staff education, to-
gether with access to adequate and appropriate supplies.
A means for documentation of urinary catheter use, in-
cluding indications and dates of insertion and removal,
should be established. Where an electronic patient record
is used, documentation of catheter use and automatic re-
minders for removal should be incorporated into this rec-
ord. The development and implementation of “bundles”
for prevention of catheter acquired urinary tract infections
has been described. Introduction of a urinary catheter
bundle which included education, catheter insertion and
management guidelines, and CA-UTI surveillance, in in-
tensive care units in 15 developing countries was followed
by a 37% reduction in CA-UTI rate [15]. A state wide
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specific practical recommendations addressing imple-
mentation under the concepts of “engage and educate”,
“execute” and “evaluate” [59].
Avoidance of catheter use
The single most important intervention to prevent CA-
UTI is to avoid use of an indwelling urinary catheter.
There are only a limited number of accepted indications
for catheter use [46]:
 Monitoring of hourly urine output in acutely ill
patients.
 Perioperative use for selected surgical procedures
Urologic surgery
Surgery on contiguous structures of the
genitourinary tract
Large volume infusions or diuretics during surgery
Requirement for intraoperative monitoring of
urine output
 Management of acute urinary retention and urinary
obstruction.
 To facilitate healing of open pressure ulcers or skin
grafts in selected patients with urinary incontinence.
 In exceptional circumstances (e.g. end-of-life care),
at patient request to improve comfort.
Alternate voiding management strategies such as inter-
mittent catheterization or, for men, external condom cathe-
ters, should be used when possible. Institutional policies
should also minimize perioperative catheter use by promot-
ing early post-procedure catheter removal and monitoring
of bladder volume with ultrasound bladder scanners, where
available, to limit catheter reinsertion for potential urinary
retention. When a catheter is indicated, it should be re-
moved promptly once it is no longer required. Patients
with indwelling catheters should be identified and reviewed
on a continuing basis, preferably at daily rounds, and the
catheter removed when no longer indicated. Catheters
have been reported to frequently remain in situ beyond
necessary, sometimes because health-care personnel are
not aware the catheter is present [7,52]. A systematic re-
view of catheter discontinuation strategies for hospitalized
patients reported that the intervention of a “stop order”
to facilitate prompt removal of unnecessary catheters
reduced the duration of catheter use by 1.06 days, and use
of either catheter reminders or stop orders decreased the
CA-UTI rate by 53% [60].
Selection of urinary catheter
The smallest gauge catheter possible should be used, to
minimize urethral trauma [4,52]. Infection risks are simi-
lar with latex or silicone catheters, and whether or not
there is hydrogel coating of the catheter. Residents withchronic catheters have a decreased frequency of obstruc-
tion with silicone catheters, but this observation is at-
tributed to the larger bore size of the catheter, rather
than the catheter material. The use of silver alloy coated
catheters does not decrease the frequency of CA-UTI
[12,61-63]. Nitrofurazone coated catheters have been re-
ported to be associated with a small decrease in CA-UTI
[12], but are accompanied by more frequent catheter re-
moval and increased catheter discomfort. Thus, current
evidence does not support the routine use of antimicro-
bial coated catheters [52].
Catheter insertion and maintenance












Obtain urine samples aseptically
Replace system if breaks in asepsis
Avoid irrigation for purpose of prevention of
infection
These recommendations are primarily based on consen-
sus, but there is strong evidence supporting a decreased
rate of acquisition of bacteriuria by maintaining a closed
drainage system. There are no benefits with routine daily
periurethral cleaning using normal saline, soap, or an anti-
septic [52,64], or with the addition of antiseptics to the
drainage bag [52].
Monitoring of infection
The surveillance of catheter use and complications is
important to document the facility CA-UTI rate, the ef-
fectiveness of interventions, and to allow comparison
with benchmark rates [7,52]. Surveillance with bench-
marking was reported, by itself, to decrease infection
rates in German intensive care units, although the impact
for CA-UTI was not as great as observed for ventilator-
associated pneumonia or primary blood stream infections
[14]. Standardized surveillance definitions for infection
should be used [52]. Core data elements which must be
collected to support effective surveillance include record-
ing of catheter indication, catheter insertion and removal
dates, urine culture results, and monitoring of bacteremia.
Relevant quality indicators are CA-UTI incidence, CA-
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ing catheter use meeting accepted indications.
The outcomes of CA-UTI and bacteremic infection are
described using a denominator of device days [52]. However,
an effective infection prevention program will minimize
catheter use, potentially leading to overall higher device
day infection rates as fewer low-risk patients will have
catheters [65,66]. Thus, an outcome based on total patient
days, the standardized infection ratio, should also be
reported [7]. Surveillance data should be reviewed by ap-
propriate individuals and committees, and observations
reported back to caregivers on patient wards [7,52].
Prevention of CA-UTI in long term care facilities
The prevention of CA-UTI in long term care facilities
addresses primarily residents with a chronic indwelling
catheter [4,24,28]. There should be frequent, systematic
review of any resident with a chronic indwelling catheter
to determine whether the catheter remains necessary.
Bacteriuria in these residents is not avoidable. Interven-
tions should focus on removing the catheter, whenever
feasible, minimizing catheter trauma, and early identifi-
cation of catheter obstruction. Chronic indwelling cathe-
ters should not be changed routinely. They should be
replaced only if there is obstruction or other malfunc-
tion, or prior to initiating antimicrobial therapy when
symptomatic urinary infection is treated [52]. Residents
with chronic catheters may use a leg bag for drainage to
facilitate mobility. Facility policies should address reuse
and cleaning or replacement of the leg bags [67]. Anti-
microbial therapy for the treatment of bacteriuria in
long term care residents with chronic indwelling cathe-
ters does not decrease CA-UTI, but there is an increased
isolation of resistant organisms with the antimicrobial
therapy. Thus, treatment of asymptomatic bacteriuria
should be avoided [24].
Conclusions
CA-UTI is an important device-associated health care
acquired infection. The use of an indwelling urethral
catheter is associated with an increased frequency of
symptomatic urinary tract infection and bacteremia, and
additional morbidity from non-infectious complications.
Infection control programs must develop, implement,
and monitor policies and practices to minimize infec-
tions associated with use of these devices. A major focus
of these programs should be to limit the use of indwell-
ing urethral catheters, and to remove catheters promptly
when no longer required. Ultimately, however, the avoid-
ance of CA-ASB will likely require development of bio-
film resistant catheter materials.Competing interests
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